Quoin Pharmaceuticals Ltd. (QNRX) Wins EMA Orphan Drug Designation for QRX003

Quoin Pharmaceuticals (QNRX) received EMA Orphan Drug Designation for QRX003 to treat Peeling Skin Syndrome, a rare skin disorder. The designation offers development incentives and potential market exclusivity. QNRX plans to start clinical trials for PSS by year-end. QRX003 has also received U.S. and Japanese designations for rare diseases. QNRX stock closed at $4.15, down 4.82%.

Quoin Pharmaceuticals (QNRX) announced that the European Medicines Agency granted Orphan Drug Designation to its lead candidate QRX003 for Peeling Skin Syndrome. This status offers incentives and potential market exclusivity. The company is on track to launch a clinical study by year-end. Analysts have a $14.00 price target, but Spark's AI rates it Neutral due to financial performance and technicals.

Quoin Pharmaceuticals (QNRX) received EMA Orphan Drug Designation for QRX003, a treatment for Peeling Skin Syndrome. The designation offers regulatory incentives, including market exclusivity. The company plans to start its first formal clinical study for the condition before year-end. QRX003 also has US pediatric rare disease and Fast Track designations.

Quoin Pharmaceuticals (QNRX) received EU orphan drug status for QRX003, a treatment for Peeling Skin Syndrome, offering benefits like fee reductions and market exclusivity. The company plans a clinical trial by late 2026. QRX003 also has US and Japanese orphan drug designations for Netherton Syndrome, with late-stage trials ongoing. Quoin focuses on rare disease treatments.

Quoin Pharmaceuticals Ltd. (QNRX) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome – Company on track to initiate first-ever formal clinical trial in Peeling Skin Syndrome before year end – Orphan Drug

Quoin Pharmaceuticals (QNRX) announced that its lead product QRX003 received Orphan Drug Designation in Europe for treating Peeling Skin Syndrome. This designation provides 10 years of market exclusivity upon approval and includes benefits like fee reductions and access to EU grants. The company plans to initiate the first formal clinical trial for Peeling Skin Syndrome by year-end. QRX003 has also received multiple regulatory designations for Netherton Syndrome in the US, Europe, and Japan.